tracking pixel


The webinar will start with a 40 minute discussion as they debrief the details of the recent FDA decision on the approval of MDMA-assisted therapy for medical use in treating PTSD. This groundbreaking decision is set to revolutionize the treatment landscape for PTSD and the webinar will provide comprehensive insights into its implications for patients, healthcare providers, and the mental health industry.

Following the discussion, we will open the floor to a Q&A session on Zoom, providing you with a unique opportunity to ask questions on the announcement. Whether you’re a mental health professional, a researcher, or someone with a personal or professional interest in MDMA and PTSD we plan to bring new insights and understanding to the news and what impact the decision will have. We hope you will join us for the live program but we will record the discussion for those who can’t attend. 

Key Topics:

  • Overview of the FDA’s decision and the process of drug approval.
  • Examination of the clinical trials and research evidence supporting MDMA-AT for PTSD.
  • Practical advice for clinicians on how to discuss the availability of MDMA-AT with patients, accounting for timelines of additional research and/or commercialization.
  • Discussion on the regulatory, ethical, and logistical considerations of implementing MDMA-AT.
  • Future perspectives on the potential for further approvals of psychedelic therapies and the evolution of psychedelic medicine.

Don’t miss this opportunity to hear from top experts in the field and gain a deeper understanding of the FDA’s decision and its profound impact on the future of PTSD treatment.